MUMBAI, India, July 11 -- Intellectual Property India has published a patent application (202511037824 A) filed by Dr. Minakshi Garg; Priyanka Nagar; and Dr. Robin Kumar, New Delhi, on April 18, for 'stable liquid injectable formulation of relugolix.'
Inventor(s) include Dr. Minakshi Garg; Priyanka Nagar; and Dr. Robin Kumar.
The application for the patent was published on July 11, under issue no. 28/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to a stable liquid injectable formulation of Relugolix designed to enhance stability and improve pharmacokinetic properties compared to oral administration. The formulation comprises Relugolix as the active pharmaceutical ingredient, citric acid as a pH adjuster and solubility enhancer, and water for injection as a vehicle. The optimized formulation contains Relugolix at a concentration of 120mg/2mL, with citric acid in the range of 0.5% to 2.0% (w/v), preferably 1.5% (w/v), to ensure solubility and stability without precipitation. The pH of the solution is maintained between 4 and 5 for optimal compatibility with intravenous administration. The developed formulation is packaged in a single-vial presentation to maintain sterility and remains stable under normal and stress conditions for at least six months. A method for preparing the injectable formulation is also disclosed, involving dissolution, sterile filtration, vial filling, and controlled storage to ensure stability and therapeutic efficacy. The developed liquid injectable formulation offers a promising alternative for the treatment of hormone dependent conditions including but not limited to prostate cancer."
Disclaimer: Curated by HT Syndication.
